



IBA to install Spain's first proton therapy center

Contract signed with Quirónsalud to install a Proteus®ONE solution in Madrid

Louvain-La-Neuve, Belgium, 23 February 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract with Quirónsalud, Spain's leading hospital group and part of Germany's Helios Group, to install a *Proteus®ONE** compact proton therapy solution in Madrid.

The contract covers delivery of a *Proteus®ONE* solution, including latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities and a long-term maintenance agreement. The hospital group will also benefit from Penn Medicine and IBA's world leading proton therapy clinical education program. The hospital will be ready to start treating patients by 2019.

The typical end-user price for a *Proteus®ONE* system with a maintenance contract is between EUR 35 and 40 million. This will be IBA's 18th installation of the compact single-room proton therapy solution.

Olivier Legrain, Chief Executive Officer of IBA, commented: "IBA's first entry into the Spanish market demonstrates the ongoing appeal of IBA's single room solution, *Proteus®ONE*. Being selected by Quirónsalud to install the first proton therapy solution in Spain, reinforces our position as the global proton therapy market leader and will bring access to the most advanced radiation therapy technology to cancer patients to this region."

Leticia Moral Iglesias, General Director of Care, Quality and Innovation of Quirónsalud group, commented: "Our mission is to improve the health of patients and this can only be done by providing the highest quality health service. After the recent merger with Fresenius Helios, we are excited to partner with IBA to bring the world's leading proton beam therapy equipment to cancer patients in Iberia for the first time. This innovative technology will enable us to 'paint' tumours with a super-fine beam of protons, destroying the cancer cells whilst limiting the exposure of healthy tissues surrounding the tumor and reducing the risk of secondary cancers. At Quirónsalud, we believe that this state-of-the-art technology will also attract patients from other countries."

ENDS



About Proteus®ONE

Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. *Proteus®ONE* is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. *Proteus®ONE* makes proton therapy easy.

* *Proteus®ONE* is the brand name of *Proteus®235*

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Quirónsalud

Quirónsalud is the most important hospital group in Spain and the third in Europe. It is located in 13 different regions and has the most advanced technology. Quirónsalud offers more than 6,200 beds in more than 100 centers, such as Fundación Jiménez Díaz, Hospital Quirónsalud Madrid, Hospital Universitario Dexeus, Ruber, Centro Médico Teknon, Hospital La Luz, Policlínica de Guipúzcoa, etc. Quirónsalud also has a large team of highly specialized professionals of international prestige.

We work in the promotion of teaching (with seven university hospitals) and medical scientific research (with the FJD's Instituto de Investigación Sanitaria, the unique private research center accredited by the Secretaria de Estado de Investigación, Desarrollo e Innovación).

Our care service is organized in units and transversal networks that allow us to optimize our experience developed in the different centers, as well as the clinical translation of our research. Presently, Quirónsalud develops numerous research projects throughout Spain and many of its centers perform a leading role in several fields, by being pioneers in different specialties such as cardiology, endocrinology, gynecology, neurology, oncology, and sports medicine, among others.

More information can be found at: www.quironsalud.es

Press Release

Regulated information



For further information, please contact:

IBA

Jean-Marc Bothy
Chief Strategy Officer

Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Press release | 02/23/2017

IBA | Ion Beam Applications SA

Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Nivelles | VAT : 0428.750.985
T +32 10 47 58 11 | F +32 10 47 58 10 | info@iba-group.com | iba-worldwide.com

**PROTECT +
ENHANCE +
SAVE LIVES**